EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSBMUG00000021612
Gene Symbol: TP53
3 Cross references
254 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSBMUG00000018733
Gene Symbol: TYR
3 Cross references
266 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSBMUG00000020405
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSBMUG00000013646
Gene Symbol: TYK2
3 Cross references
197 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSBMUG00000017166
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Itk/tsk-Like

Ensembl ID : ENSBMUG00000011342
Gene Symbol: LOC102287219
2 Cross references
206 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSBMUG00000015691
Gene Symbol: UTS2R
3 Cross references
92 Possible Orthologues:

Utrophin

Ensembl ID : ENSBMUG00000007061
Gene Symbol: UTRN
3 Cross references
268 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSBMUG00000011996
Gene Symbol: VEGFA
2 Cross references
254 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSBMUG00000001652
Gene Symbol: VDR
3 Cross references
466 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSBMUG00000025402
Gene Symbol: VKORC1
3 Cross references
190 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSBMUG00000019809
Gene Symbol: XDH
3 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).